Clinical trial
2 Years Prospective Study to Collect Real-life Data On the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial spondyloarthriTis (PROMPT)
NCT05155098 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- 2 Years Prospective Study to Collect Real-life Data On the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial spondyloarthriTis (PROMPT)
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Observational
- Overall status
- Completed
- Start date
- March 25, 2022
- Completion date
- August 20, 2025
- Enrollment
- 127 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.
ankylosing spondylitis, moderate to severe plaque psoriasis, non-radiographic axial spondyloarthritis, psoriatic arthritis